Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Accumulated Expenses: 2014-2020

Historic Other Accumulated Expenses for Myriad Genetics (MYGN) over the last 5 years, with Jun 2020 value amounting to $22.4 million.

  • Myriad Genetics' Other Accumulated Expenses rose 24.44% to $22.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $22.4 million, marking a year-over-year increase of 24.44%. This contributed to the annual value of $22.4 million for FY2020, which is 24.44% up from last year.
  • Myriad Genetics' Other Accumulated Expenses amounted to $22.4 million in Q2 2020, which was up 420.93% from $4.3 million recorded in Q1 2020.
  • Myriad Genetics' Other Accumulated Expenses' 5-year high stood at $22.4 million during Q2 2020, with a 5-year trough of $4.3 million in Q1 2020.
  • For the 3-year period, Myriad Genetics' Other Accumulated Expenses averaged around $14.9 million, with its median value being $16.1 million (2018).
  • As far as peak fluctuations go, Myriad Genetics' Other Accumulated Expenses spiked by 84.81% in 2016, and later crashed by 80.09% in 2020.
  • Myriad Genetics' Other Accumulated Expenses (Quarterly) stood at $13.7 million in 2016, then rose by 13.87% to $15.6 million in 2017, then climbed by 13.46% to $17.7 million in 2018, then tumbled by 53.67% to $8.2 million in 2019, then rose by 24.44% to $22.4 million in 2020.
  • Its Other Accumulated Expenses stands at $22.4 million for Q2 2020, versus $4.3 million for Q1 2020 and $8.2 million for Q4 2019.